Spyre reports positive IBD data; shares rally amid $400M funding raise
Spyre Therapeutics announced Q3 2026 financials, highlighting potential best-in-class candidate SPY003 for IBD and announcing a $400M public offering to advance its HS program.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed